Alexion Pharmaceuticals, Inc. (ALXN) Stake Boosted by Zurcher Kantonalbank Zurich Cantonalbank

(ALXN)’s stock declined 11.63%. The Aristotle Capital Management Llc holds 1.67 million shares with $172.55 million value, down from 1.71M last quarter. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since September 2, 2016 and is downtrending. The stock increased 0.72% or $0.46 on August 31, reaching $64.71. About 84,703 shares traded.

Quantitative Investment Management Llc decreased its stake in Alexion Pharmaceuticals Inc (ALXN) by 62.89% based on its latest 2016Q4 regulatory filing with the SEC. It has underperformed by 34.82% the S&P500. Spot Trading Llc who had been investing in Du Pont E I De Nemours & Co (Put) for a number of months, seems to be bullish on the $73.48 billion market cap company. The Firm operates in two divisions: High Performance Products (HPP) and Technology Solutions (TS). The HPP segment comprises two product lines: its Multicomputer product portfolio of computing systems for digital signal processing (DSP) applications within the defense market, and its Myricom product line of network Ethernet adapters that are offered to both commercial and government customers.

Investors sentiment increased to 1.37 in 2016 Q4. Its down 0.03, from 0.8 in 2016Q3. The stock was sold at an average price of $137.74, for a total value of $96,418.00.

A number of other institutional investors have also modified their holdings of ALXN. 215.83 million shares or 2.26% more from 211.05 million shares in 2016Q3 were reported. Clearbridge Investments Limited Liability, New York-based fund reported 2.27 million shares. 10 owns 2.72% invested in E I Du Pont De Nemours And Co (NYSE:DD) for 132,175 shares.

Iguana Healthcare Management Llc decreased Alexion Pharmaceuticals Inc (ALXN) stake by 26.67% reported in 2016Q4 SEC filing. (NASDAQ:ALXN) recently. Julie O’neill, EVP reported the sale of 11,160 shares of (ALXN). ALXN comes in with a P/S ratio of 9.07 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector and its peers. Lazard Asset Mngmt Limited Liability Co has invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Moreover, Envestnet Asset Mngmt has 0.01% invested in Alexion Pharmaceuticals, Inc. Chilton Cap Management Llc owns 105,721 shares or 0.81% of their United States portfolio. (NASDAQ:ALXN). University Of Texas Managment invested 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. The number of shares now owned by investors are 223.57 mln. Janney Montgomery Scott Llc has invested 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Ridgeworth Lc holds 0.16% or 151,785 shares. Korea Invest accumulated 340,585 shares. Alexion Pharmaceuticals Inc. had 68 analyst reports since July 27, 2015 according to SRatingsIntel. The analyst recommendations from a month ago are 3 Buy, 0 Overweight, 0 Sell, 2 Hold and 0 Underweight. Therefore 44% are positive. Deutsche Bank AG lowered their price target on Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. On May 25 the stock rating was upgraded from “Equal-Weight” to “Overweight” by analysts at Morgan Stanley. The stock of Alexion Pharmaceuticals, Inc. The rating was upgraded by BMO Capital Markets to “Outperform” on Friday, April 29. ADVISORS LP on Wednesday, June 14. RBC Capital Markets maintained Deere & Company (NYSE:DE) on Monday, August 22 with “Sector Perform” rating. Robert W. Baird maintained Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 138.45 on Thursday. The stock now has a consensus rating of “Buy” and a consensus target price of $156.13. On Friday, July 28 the stock rating was maintained by BMO Capital Markets with “Outperform”.

More important recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, July 31 with “Buy” rating. The rating was maintained by Argus Research on Tuesday, December 8 with “Buy”. (NASDAQ:ALXN) earned “Buy” rating by Goldman Sachs on Friday, October 28. BAKER BROS. ADVISORS LP bought $77.53 million worth of stock or 660,779 shares. The fund acquired 4,000 shares of the biopharmaceutical company’s stock, valued at approximately $487,000. $97,511 worth of Alexion Pharmaceuticals, Inc. Another trade for 10,000 shares valued at $1.17M was made by HANTSON LUDWIG on Wednesday, June 14. 6,472 shares valued at $1.55M were sold by LLOYD ANNE H on Wednesday, May 3. It also upped Ishares Msci Canada Index (EWC) stake by 256,088 shares and now owns 917,535 shares. Cigna Corporation (NYSE:CI) was raised too.

Bridgeway Capital Management Inc holds 0.01% of its portfolio in CSP Inc. for 38,700 shares. The Iguana Healthcare Management Llc holds 55,000 shares with $6.73 million value, down from 75,000 last quarter.

Aristotle Capital Management Llc increased Oshkosh Corp (NYSE:OSK) stake by 66,762 shares to 4.08M valued at $263.64 million in 2016Q4.

Leave a Reply

Your email address will not be published. Required fields are marked *